Journal of Nature and Science (JNSCI), Vol.3, No.8, e418, 2017

Neuroscience

 

Acromegaly: Underdiagnosed in Patients with Prolactinoma

 

Ekaterina Manuylova1, G. Edward Vates2, and Ismat Shafiq1,*

 

1 Department of Endocrinology, Diabetes and Metabolism, University of Rochester, 601 Elmwood Ave, Rochester, NY, USA.

2 Department of Neurosurgery, University of Rochester, 2180 South Clinton Ave, Rochester, NY, USA


Prolactin secreting adenomas are very common and account for 50-60% of all functional pituitary adenomas.  Medical history pertaining to reproductive and sexual function initiates the work up for prolactinoma. At the time of initial assessment other pituitary hormones may be evaluated, including growth hormone (GH). Thereafter, patients are treated medically with dopamine agonist, typically with no further assessment of GH hypersecretion. Review of the literature suggests that up to 4% of patients with an established diagnosis of prolactinoma can develop acromegaly even after many years of the initial evaluation. Acromegaly is a rare disease with mortality rates 2-3 times higher as compared to that of the general population. The interval from onset of symptoms to the diagnosis may range from one year to several decades. Thus, omitting IGF-1 measurements at the initial evaluation of prolactinoma, and/or in the follow up period, can miss mild and subtle cases of acromegaly. Therefore, biochemical evaluation for GH excess should be considered in patients with prolactinoma initially as well as in the remote follow up.

 

Acromegaly | Prolactinoma | Growth hormone | Pituitary | Insulin like growth factor

 

Background

Prolactinoma is the most common functional pituitary adenoma [1, 2]. The initial assessment starts by checking the prolactin (Prl) level for evaluation of hypogonadism and/or infertility. Upon presentation, other pituitary hormones, including growth hormone, may also be checked [6, 7] but thereafter no further assessment for co-section is routinely recommended. Prolactin producing adenomas are known to co-secrete growth hormone (GH) [3-5]. GH excess can be detected at the initial diagnosis or many years later. Based on available literature approximately 4% of patients with prolactinoma develop acromegaly in the remote follow up period [3, 8]. Acromegaly has an insidious nature. The related co-morbidities such as diabetes, hypertension, and cardiovascular disease are commonly seen in the general population and may not raise a suspicion for GH excess. Untreated acromegaly has a 2-3 times higher mortality rate as compared to the general population. Thus, it is paramount to evaluate patients with prolactinoma periodically for the development of acromegaly. In this paper we present the current recommendations for diagnosing prolactinoma followed by review of GH/Prl co-secretion adenomas.

 

General approach to diagnosis of prolactinoma:

Pituitary adenomas are very common with an approximate prevalence of 10.6 % based on autopsy series [9]. About 40% of pituitary adenomas are prolactin producing adenomas. The disease comes into clinical consideration frequently due to the nature of its presentation.  The common symptoms in women are galactorrhea, amenorrhea and infertility, while in men the symptoms of hypogonadism prevail. The diagnosis is easily established by checking serum prolactin level followed by gadolinium-enhanced head MRI, after ruling out physiologic and pharmacologic causes of hyperprolactinemia [2, 7]. Other hormones like cortisol and GH levels may be assessed initially to rule out co-secretion [2, 6] but the guidelines do not routinely recommend checking them in all patients with prolactin producing adenomas [2, 7].

 

GH/Prl Co-secreting Adenomas

Prevalence

GH/Prl co-secretion is well recognized. Up to 25% of growth hormone (GH) secreting adenomas co-secrete prolactin [16-18]. In contrary, the frequency of GH secretion in established prolactinoma cases is thought to be rare. In 1977 Kleinberg et al reported that 8 out of 48 prolactinoma patients had biochemical and clinical acromegaly, with a prevalence of 17%.  However, this may be under or overestimated, given the technical challenges associated with measuring Prl and GH levels.

 

Histological Types:

Histologically, three different types of combined GH/Prl pituitary adenomas have been described. The first and most common type of GH/Prl co-secreting adenoma originates from both somatotrophs and lactotrophs. These adenomas have two distinctive cell types on the immunohistochemistry staining for GH and Prl [20]. The second type of combined GH/Prl secreting pituitary lesion is a monomorphous mammosomatotroph adenoma with GH and Prl hormones produced by a single cell. This type accounts for 8 to 10 % of GH-secreting tumors. Clinically, in both types, patients have signs and symptoms of acromegaly with limited manifestation from the hyperprolactinemia [18, 20]. The third and the last type of combined GH/Prl co-secreting adenoma is a primitive acidophilic stem cell adenoma, also with dual hormone secretion by a single cell. It is a very rare subtype and only described in case reports [13, 21, 22], more often in teenagers and younger adults. Clinically, symptoms from hyperprolactinemia are more prevalent in these patients, followed by presentation of acromegaly. The clinical course of acidophilic stem cell adenomas is usually aggressive requiring multiple surgeries and additional treatments.

 

Pathogenesis

The pathogenesis of mixed GH/Prl pituitary adenomas is not fully understood. It thought to be due to the development of somatotrophs and lactotrophs from a single progenitor cell during embryogenesis, under regulation of Prop1 and Pit1 transcription factors [1, 15]. However, recent literature also suggests that the anterior pituitary has a group of polyclonal cells that are capable to differentiate from one pituitary cell line to another, especially under physiologic demand. This process, termed as í░transdifferentiationí▒ is described by Senovilla et al [23]. These multifunction cells are more prominent in pituitary adenomas, thus this process can explain the development of combined GH/Prl adenomas. However, the stimulus that precipitates this transdifferentiation in GH/Prl adenomas is not known. Lania et al described a case of aggressive prolactinoma that evolved into a GH secreting adenoma presumably due to GNAS gene mutation [12].

High Mobility Group A (HMGA) protein has been shown to play a role in the development of pituitary adenoma. Fedele et al showed that overexpression of HMGA1 in transgenic mice leads to development of mixed GH/Prl pituitary adenomas [24]. Esposito et all further showed that overexpression of the pseudogenes HMGA1P6 and HMGA1P7 increases HMGA1 levels, especially in GH and nonfunctioning pituitary adenomas, leading to tumor formation [25]. Furthermore, Wang et al showed HMGA1 to be associated with aggressive and invasive pituitary adenomas [26]. Thus, HMGA1 may have a critical role in the growth of these cells. The role of these proteins is unclear in prolactinoma and/or mixed GH/Prl adenomas and further studies are needed to understand the pathogenesis to better formulate the management plan for patients with prolactinomas.

 

Late Development of Acromegaly in Prolactinoma Patients

Number of case reports describe late development of acromegaly in prolactinoma patients with variable presentation [3, 4, 8, 10-14]. The time between initial diagnosis of prolactinoma to development of acromegaly ranged from 2 [3] to 20 years [4, 5]. Some patients were reported to be resistant to dopaminergic treatment [12] while others were well controlled on medical treatment, developing acromegaly after many years [4].

There are two recent studies that examined the incidence of acromegaly in prolactinoma patients [3, 8]. Anderson et al [3] periodically monitored 78 prolactinoma patients from 1996 to 2001 with IGF-1 levels. 3 out of 78 patients with initial normal for age and gender IGF-1 levels developed clinical and biochemical acromegaly. The time interval from the initiation of screening until the second diagnosis was 29, 40 and 60 months. Of note, one patient underwent pituitary surgery before the diagnosis of acromegaly and the pathology revealed only Prl signal, raising the question of whether or not acromegaly originated from the same lesion or if the patient had two separate lesions, as a similar case was described in the literature [14].  Two other patients underwent pituitary surgery after the diagnosis of acromegaly and in both GH reactivity was present.  However, there was only one patient where prolactin was positivity detected in the separate cell population, again raising the same question of original source. Isolated IGF-1 elevation with appropriate GH suppression during glucose suppression testing was documented in another 5 out of 78 patients. The clinical significance of the isolated IGF-1 is not completely understood as there is no further follow up on these patients to see whether or not there was an earlier presentation of acromegaly.

Rosario et al [8] studied 121 patients with prolactinoma with no clinical and biochemical evidence of acromegaly at the initial diagnosis. They were treated with dopaminergic agonists with adequate response for 5 years. Five patients developed biochemical acromegaly by the end of the 5 years despite having well controlled prolactinoma on medical treatment. Four patients were female and one was male. Four individuals had macroadenoma and one had microadenoma. Two patients underwent pituitary surgery with immunohistochemical staining confirming co-secreting GH/Prl adenomas. The intervals between prolactinoma and acromegaly diagnoses were not reported in this article.

In each of the studies [3, 8], acromegaly developed in approximately 4% of included patients during the remote follow up period.  This is suggestive that the prevalence could be even higher than 4% if the patients are followed for longer period of time. More and larger studies, however, are needed to delineate this question.

 

Conclusion

Prolactinoma is the most common secretory pituitary adenoma. Subset of patients do present with GH co-secretion which is detected either at the time of diagnosis or decades later. Acromegaly has an insidious nature and co-morbidities, such as diabetes, and cardiovascular disease, are very common in the general population and may not raise the suspicion for GH excess. As a result the diagnosis is often delayed. Untreated acromegaly has a mortality rates 2-3 times higher as compared to the general population, mostly due to cardiomyopathy and cardiac valve abnormalities [16]. Therefore, based on the literature review, we recommend checking IGF-1 on the initial assessment as well as periodically thereafter. More studies can delineate the optimal interval and the duration of biochemical evaluation in this patient population.


 

 

 


1.  Kars, M., et al., Update in prolactinomas. Neth J Med, 2010. 68(3): p. 104-12.

2.  Melmed, S., et al., Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011. 96(2): p. 273-88.

3.  Andersen, M., et al., Development of acromegaly in patients with prolactinomas. Eur J Endocrinol, 2003. 149(1): p. 17-22.

4.  Manuylova, E., et al., Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Rep, 2016. 2016.

5.  Dessimoz, C., et al., Transformation of a microprolactinoma into a mixed growth hormone and prolactin-secreting pituitary adenoma. Front Endocrinol (Lausanne), 2011. 2: p. 116.

6.  Wong, A., et al., Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges. J Clin Neurosci, 2015. 22(10): p. 1562-7.

7.  Casanueva, F.F., et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf), 2006. 65(2): p. 265-73.

8.  Rosario, P.W. and S. Purisch, Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists. Arq Bras Endocrinol Metabol, 2010. 54(6): p. 546-9.

9.  Paschou, S.A., A. Vryonidou, and D.G. Goulis, Pituitary incidentalomas: A guide to assessment, treatment and follow-up. Maturitas, 2016. 92: p. 143-9.

10.   Bonert, V.S. and S. Melmed, Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab, 2006. 2(7): p. 408-12; quiz following 412.

11.   Kageyama, K., et al., A case of macroprolactinoma with subclinical growth hormone production. Endocr J, 2002. 49(1): p. 41-7.

12.   Lania, A.G., et al., Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab, 2010. 95(1): p. 13-7.

13.   Page, M.D., et al., Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma. J Clin Endocrinol Metab, 1996. 81(12): p. 4484-7.

14.   Rahman, M., et al., Synchronous GH- and prolactin-secreting pituitary adenomas. Endocrinol Diabetes Metab Case Rep, 2014. 2014: p. 140052.

15.   Dasen, J.S. and M.G. Rosenfeld, Signaling and transcriptional mechanisms in pituitary development. Annu Rev Neurosci, 2001. 24: p. 327-55.

16.   Melmed, S., Medical progress: Acromegaly. N Engl J Med, 2006. 355(24): p. 2558-73.

17.   Wang, M., et al., The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol, 2012. 166(5): p. 797-802.

18.   Kreutzer, J., et al., Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab, 2001. 86(9): p. 4072-7.

19.   Kleinberg, D.L., G.L. Noel, and A.G. Frantz, Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med, 1977. 296(11): p. 589-600.

20.   Lopes, M.B., Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus, 2010. 29(4): p. E2.

21.   Horvath, E., et al., Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer, 1981. 47(4): p. 761-71.

22.   Maheshwari, H.G., et al., Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab, 2000. 85(9): p. 3409-16.

23.   Senovilla, L., et al., Multifunctional cells in human pituitary adenomas: implications for paradoxical secretion and tumorigenesis. J Clin Endocrinol Metab, 2004. 89(9): p. 4545-52.

24.   Fedele, M., et al., Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene, 2005. 24(21): p. 3427-35.

25.   Esposito, F., et al., HMGA1-pseudogene expression is induced in human pituitary tumors. Cell Cycle, 2015. 14(9): p. 1471-5.

26.   Wang, E.L., et al., Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. Histopathology, 2010. 56(4): p. 501-9.

27.   Reid, T.J., et al., Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf), 2010. 72(2): p. 203-8.


 


Conflict of Interest: No conflicts declared.

* Corresponding Author: Ismat Shafiq, MD

Telephone: 1-585-275-2901; Fax: 1-585-273-1288.

Email: Ismat_Shafiq@urmc.rochester.edu.

© 2017 by the Journal of Nature and Science (JNSCI).